Company profile
Organon & Co.
NYSE: OGN · Healthcare · Drug Manufacturers - General
#50 of 1,422 Healthcare companies by revenue37th-percentile growth
EA Score
66BFH 75DQ 56GM 59SS 68
v0.1 · 65/100 weight · provisional
↑ growth stability, return on equity · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$6.2B
Rev growth YoY (TTM)
-2.1%
Net income (FY)
$187.0M
Employees
10,000
as of 2026-08-08
Market cap
$3.6B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.2B$6.2B2025
Net income$187.0M$187.0M2025
Total assets$12.9B$12.9B2025
Liabilities$12.1B$12.1B2025
Equity$752.0M$752.0M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Organon & Co.’s revenue?
Organon & Co. booked $6.2B in FY2025 revenue, contracting 2.9% year over year — slower than 63% of Healthcare companies we track, at a 3.0% net margin.
Peers · Healthcare
Agilent Technologies, Inc.85AAvantor, Inc.68BArdent Health Inc.61CEdwards Lifesciences Corporation86ASTERIS plc76B+Encompass Health Corporation76B+Neighbors
Hudson →Key facts
CEOJoseph T. Morrissey Jr.
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersJersey City, NJ
ExchangeNYSE: OGN
Employees10,000
IPO date2021-05-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.